https://www.selleckchem.com/products/gs-9973.html
Facioscapulohumeral muscular dystrophy (FSHD) is a patchy and slowly progressive disease of skeletal muscle. For MRI to be a useful biomarker in an FSHD clinical trial, it should reliably detect changes over relatively short time-intervals (~ 1 year). We hypothesized that fatty change over the study course would be most likely in muscles already demonstrating disease progression, and that the degree of MRI burden would be correlated with function. We studied 36 patients with FSHD and lower-extremity weakness at baseline. Thirty-two pati
Like
Comment
Share
